Does vaccination with an mRNA COVID-19 vaccine introduce a particular risk of worsening for patients with pre-existing cardiovascular (CV) diseases? That was the central question assessed by Dr Anthony Simone (Kaiser Permanente Los Angeles Medical Center, CA, USA) and his fellow researchers [1]. They evaluated CV hospitalisations of adult patients with a history of a CV condition within 30 days after their vaccination compared with the expected incidence of CV hospitalisation (control) using data obtained from the same population during the same 30-day calendar period 2 years prior (a baseline period before the COVID-19 pandemic).
Out of a cohort of 229,829 patients with CV conditions, 165,711 who had received at least 1 dose of an mRNA-based vaccination were included. 160,482 of the included patients were vaccinated at least twice (38.7% mRNA-1273 and 31.2% BNT162b2). Prior diagnoses included atrial fibrillation, myocarditis, coronary artery disease, and heart failure. The baseline findings comprised a median age of 72 years, 43% women, 52% White, 25.4% Hispanic, 10.4% Asian, and 10.2% Black.
In total, admissions for CV conditions were registered for 844 patients during the 30 days following the first dose of an mRNA COVID-19 vaccine compared with 1,012 CV hospitalisations in the historical control group (odds ratio [OR] 0.86; 95% CI 0.76–0.91). After the second dose, 812 patients were hospitalised due to CV conditions compared with 960 in the control (OR 0.85; 95% CI 0.77–0.93). Of note, there were no hospital admissions in the group of patients with prior myocarditis. Looking at the hospitalisation rate of patients with CV disease after testing positive for SARS-CoV-2, the investigators found that out of 24,282 persons, 836 had to be admitted within 1 month after confirmation of the infection. Compared with controls, this translated into a nearly 5 times higher likelihood for patients with CV disease history to be hospitalised when infected with SARS-CoV-2 (OR 4.7; 95% CI 4.0–5.6).
The authors concluded that the difference in hospitalisation risk for vaccination compared with SARS-CoV-2 infection is large and suggests that the benefit of vaccination far outweighs the risks.
- Simone A, et al. Exacerbation of pre-existing cardiovascular disease following COVID-19 mRNA vaccination. EP.APS.P47, AHA Scientific Sessions 2022, 05–07 November, Chicago, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly Next Article
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality »
« Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly Next Article
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia – State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
January 11, 2023
Up-titration of HF therapies following HF discharge saves lives
January 11, 2023
Olpasiran leads to dramatic reductions in Lp(a) concentrations
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com